Market closed
Fennec Pharmaceuticals/$FENC
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Fennec Pharmaceuticals
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
Ticker
$FENC
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
32
Website
FENC Metrics
BasicAdvanced
$145M
-
-$0.02
0.36
-
Price and volume
Market cap
$145M
Beta
0.36
52-week high
$7.06
52-week low
$5.10
Financial strength
Current ratio
6.718
Quick ratio
6.031
Long term debt to equity
-351.217
Total debt to equity
-355.721
Interest coverage (TTM)
0.62%
Management effectiveness
Return on assets (TTM)
4.47%
Return on equity (TTM)
0.82%
Valuation
Price to revenue (TTM)
3.014
Price to book
-26.02
Price to tangible book (TTM)
-26.02
Price to free cash flow (TTM)
5.311
Growth
Revenue change (TTM)
123.69%
Earnings per share change (TTM)
-99.58%
3-year earnings per share growth (CAGR)
-84.36%
FENC News
AllArticlesVideos
Fennec Pharmaceuticals Inc. (FENC) Q4 2024 Earnings Call Transcript
Seeking Alpha·4 weeks ago
Fennec Pharmaceuticals Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update
GlobeNewsWire·4 weeks ago
Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2024 Financial Results on March 10, 2025
GlobeNewsWire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Fennec Pharmaceuticals stock?
Fennec Pharmaceuticals (FENC) has a market cap of $145M as of April 05, 2025.
What is the P/E ratio for Fennec Pharmaceuticals stock?
The price to earnings (P/E) ratio for Fennec Pharmaceuticals (FENC) stock is 0 as of April 05, 2025.
Does Fennec Pharmaceuticals stock pay dividends?
No, Fennec Pharmaceuticals (FENC) stock does not pay dividends to its shareholders as of April 05, 2025.
When is the next Fennec Pharmaceuticals dividend payment date?
Fennec Pharmaceuticals (FENC) stock does not pay dividends to its shareholders.
What is the beta indicator for Fennec Pharmaceuticals?
Fennec Pharmaceuticals (FENC) has a beta rating of 0.36. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.